PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2012

Sep 4, 2012

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Antisense Therapeutics Limited (ASX:ANP) ABN: 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr Mark Diamond Date of Last Notice: 24[th] July 2012

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		4thSeptember 2012
No. of securities held prior to change		Shares Options Direct 7,252,278 2,000,000 Indirect - - Total 7,252,278 2,000,000
Class		Ordinary Shares
Number acquired		Shares Options Direct 500,000 - Indirect - - Total 500,000 -

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$8,000.00
No. of securities held after change				Options 2,000,000 - 2,000,000
			Shares	Options
		Direct	7,752,278	2,000,000
		Indirect	-	-
		Total	7,752,278	2,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back		On Market Acquisition

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

==> picture [45 x 27] intentionally omitted <==

The CFO Solution 05.09.2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002